Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)
Toyota|$17.90 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.06 (¥3,959)+1.93%▲ (in JPY terms)
SoftBank|$31.29 (¥4,944)+1.90%▲ (in JPY terms)
MUFG|$22.00 (¥3,475)+1.82%▲ (in JPY terms)
Keyence|$511.18 (¥80,760)+2.27%▲ (in JPY terms)
Nintendo|$53.67 (¥8,479)+3.05%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.69%▲ (in JPY terms)
Takeda|$39.39 (¥6,223)+0.65%▲ (in JPY terms)
Tokyo Electron|$67.28 (¥10,630)+2.56%▲ (in JPY terms)
Recruit|$116.59 (¥18,420)+0.22%▲ (in JPY terms)
ITOCHU|$14.46 (¥2,284)+2.84%▲ (in JPY terms)
Honda|$11.38 (¥1,798)+1.21%▲ (in JPY terms)
Shin-Etsu|$37.84 (¥5,978)+0.25%▲ (in JPY terms)
Tokio Marine|$3.53 (¥558)+2.89%▲ (in JPY terms)
Fast Retailing|$478.39 (¥75,580)-1.07%▼ (in JPY terms)

JP3475350009

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “An announcement regarding the approval of Enhertu® and pertuzumab combination therapy for first-line treatment of HER2-positive breast cancer in China (264KB) will open in a new window as a PDF file.”

by

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “An announcement regarding the approval of Enhertu® and pertuz … 続きを読む

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “The results of the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for the first-line treatment of non-small cell lung cancer with HER2 gene mutations (270.9KB) will be displayed in a new window as a PDF file.”

by

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “The results of the Phase 3 clinical trial of trastuzumab deru … 続きを読む

2026-07-27 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) and pertuzumab combination therapy for first-line treatment of HER2-positive breast cancer (260KB) will open in a new window as a PDF file.”

by

2026-07-27 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approv … 続きを読む

2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of datopotamab deruxtecan (Dato-DXd/DS-1062) as a first-line treatment for triple-negative breast cancer (248.5KB) will open in a new window as a PDF file.”

by

2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approv … 続きを読む

Contact